Seeing Is Believing

Currently out of the existing stock ratings of Daniel Brennan, 21 are a HOLD (55.26%), 14 are a BUY (36.84%), 3 are a SELL (7.89%).
Analyst Daniel Brennan, currently employed at TD COWEN, carries an average stock price target met ratio of 61% that have a potential upside of 17.48% achieved within 137 days.
Daniel Brennan’s has documented 244 price targets and ratings displayed on 18 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on LAB, Standard Biotools at 13-Aug-2025.
Analyst best performing recommendations are on NVTA (INVITAE CORP).
The best stock recommendation documented was for NVTA (INVITAE CORP) at 7/26/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.06 (3.09%) receiving and performance score of 30.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 06-Nov-2024
$50
$13.24 (36.02%)
$55
1 months 22 days ago
(13-Feb-2026)
5/10 (50%)
$13.49 (36.95%)
125
Buy Since 11-Feb-2016
$55
$18.24 (49.62%)
$60
3 months 20 days ago
(15-Dec-2025)
5/8 (62.5%)
$9.33 (20.43%)
298
Buy Since 10-Dec-2025
$60
$26.65 (79.91%)
3 months 25 days ago
(10-Dec-2025)
0/1 (0%)
$13.08 (27.88%)
Hold Since 15-Nov-2019
$40
$3.24 (8.81%)
$48
7 months 30 days ago
(05-Aug-2025)
11/13 (84.62%)
$8.01 (25.04%)
162
Hold Since 08-May-2025
$45
$8.24 (22.42%)
$60
10 months 27 days ago
(08-May-2025)
9/9 (100%)
$4.65 (11.52%)
120
What Year was the first public recommendation made by Daniel Brennan?